The latest news

REACT: HIV reactivation and targeted removal by gene editing

QVQ has intensified its collaboration with the research group of @Monique Nijhuis (Translational Virology, UMCU). The REACT project, part of Health Holland TKI-LSH, will investigate possible utilization of our anti-HIV single domain antibody products with mRNA containing lipid nanoparticles (LNPs). We are happy to collaborate with Monique, Single Cell Discoveries and the HIV foundation in this interesting project. QVQ anticipates that the approaches aimed to be developed in this project will have the potential to be widely applicable.

Stop the no. 1 elephant killer!

Elephant Endotheliotropic Herpes Virus (EEHV) is the most common cause of death among young elephants. To aid the development of new detection agents and therapeutic intervention strategies, QVQ will contribute its lead-development to the crowdfunding project “Stop the no. 1 elephant killer!” lead by Utrecht University professors Victor Rutten and Xander de Haan. Link

VHH-Fc fusion constructs show enhanced potency in blocking HIV

Congrats to our Target2Cure collaborators, among which PhD student @Angela Schriek and under the supervision of @Marit van Gils and @Steven de Taeye (AUMC) for having published a nice study in Frontiers in Immunology.  Schriek et al. describe the development of QVQ’s anti-HIV-1 single domain antibody products Q1 (J3), Q8 (2E7) and (Q9) 1F10 into various multivalent and Fc-fused constructs. This showed increased binding to the HIV-1 envelope and enhanced neutralization potency. In addition, fusion of an IgG1 domain to J3 improved neutralization potency compared to the J3-bihead and restored Fc-mediated effector functions. Due to their neutralization breadth, potency and ability to induce effector functions, these nanobody-IgG1 constructs may prove to be valuable towards alternative HIV-1 therapies. Link